The recent FDA mandate aimed at increasing diversity in clinical trials fails to address critical issues in breast cancer treatment for Black women, according to experts. In a discussion hosted by Taylyn Washington-Harmon, BDO's clinical trials editor, Ricki Fairley, CEO of TOUCH BBCA, and Dr. Melissa Davis, a distinguished investigator at Morehouse School of Medicine, […]
